Paper · 36551663
References149
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
1 to 20 of 149
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18259690 | The epidermal growth factor receptor family: biology driving targeted therapeutics. | Cell Mol Life Sci | 2008 | https://conductscience.org/library/papers/18259690 | PubMed |
| 2 | 29383036 | Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. | Ther Adv Med Oncol | 2018 | https://conductscience.org/library/papers/29383036 | PubMed |
| 3 | 32847130 | Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32847130 | PubMed |
| 4 | 25891541 | Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer. | Lung Cancer | 2015 | https://conductscience.org/library/papers/25891541 | PubMed |
| 5 | 31548545 | Breast cancer. | Nat Rev Dis Primers | 2019 | https://conductscience.org/library/papers/31548545 | PubMed |
| 6 | 35625959 | Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35625959 | PubMed |
| 7 | 14623113 | Shc-dependent pathway is redundant but dominant in MAPK cascade activation by EGF receptors: a modeling inference. | FEBS Lett | 2003 | https://conductscience.org/library/papers/14623113 | PubMed |
| 8 | 24300455 | HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. | Eur J Cancer | 2014 | https://conductscience.org/library/papers/24300455 | PubMed |
| 9 | 26689995 | Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/26689995 | PubMed |
| 10 | 32034073 | Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32034073 | PubMed |
| 11 | 32080212 | Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. | Sci Rep | 2020 | https://conductscience.org/library/papers/32080212 | PubMed |
| 12 | 30975923 | Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. | Oncologist | 2019 | https://conductscience.org/library/papers/30975923 | PubMed |
| 13 | 35839938 | Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer. | Radiother Oncol | 2022 | https://conductscience.org/library/papers/35839938 | PubMed |
| 14 | 34320350 | ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. | Cell Rep | 2021 | https://conductscience.org/library/papers/34320350 | PubMed |
| 15 | 10880430 | The ErbB signaling network: receptor heterodimerization in development and cancer. | EMBO J | 2000 | https://conductscience.org/library/papers/10880430 | PubMed |
| 16 | 34548309 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34548309 | PubMed |
| 17 | 33750895 | Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer. | Oncogene | 2021 | https://conductscience.org/library/papers/33750895 | PubMed |
| 18 | 31519989 | ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. | Oncogene | 2020 | https://conductscience.org/library/papers/31519989 | PubMed |
| 19 | 24667376 | Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. | Sci Signal | 2014 | https://conductscience.org/library/papers/24667376 | PubMed |
| 20 | 34084213 | HER3 expression and MEK activation in non-small-cell lung carcinoma. | Lung Cancer Manag | 2021 | https://conductscience.org/library/papers/34084213 | PubMed |
papers-2026-11-12-0.1.0
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/papers/v1/36551663/references